A groundbreaking biotech company, Ibnova Therapeutics, has emerged from an ambitious partnership between Australian and Danish researchers. The new venture aims to accelerate the development of stem cell therapies for heart disease, targeting treatments for both children and adults.
A Collaborative Effort Across Borders
Ibnova Therapeutics, officially launched today, is a product of collaborative research spearheaded by the Murdoch Children’s Research Institute (MCRI) in Melbourne and QIMR Berghofer in Brisbane. The project has received significant support from the Novo Nordisk Foundation’s Center for Stem Cell Medicine (reNEW). Headquartered in Copenhagen, reNEW also operates research hubs at the University of Copenhagen, Leiden University Medical Center in the Netherlands, and MCRI in Australia.
The company’s roots are firmly planted in decades of pioneering work. Professors Enzo Porrello of MCRI and James Hudson of QIMR Berghofer have been instrumental in advancing stem cell-based treatments for heart failure. Their research demonstrated that lab-grown human heart muscle could restore heart function after a heart attack. This technique has already shown safety and efficacy in animal models.
sbb-itb-f5765c6
Support for Innovation in Biotech
Based in Denmark, Ibnova Therapeutics benefits from resources and funding provided by the BioInnovation Institute (BII) Venture Lab and the Novo Nordisk Foundation Cellerator program. These initiatives are designed to help researchers translate scientific breakthroughs into practical therapies and ready the technology for human clinical trials within the next three to five years.
"We are incredibly excited to announce the launch of Ibnova Therapeutics and move our stem cell technology towards clinical trials", said Professor Enzo Porrello, Co-Founder of Ibnova Therapeutics. "This would not have been possible without the support of reNEW and our Novo Nordisk Foundation ecosystem partners in Denmark including the Cellerator and the BioInnovation Institute."
Andrew Laskary, Executive Director, Chief Scientific Officer, and Co-Founder of Ibnova Therapeutics, highlighted the company’s mission to bridge the gap between breakthrough science and clinical application. "With Ibnova, we can now bridge the hardest gap in medicine by turning breakthrough biology into a clinical-ready therapy", he said. "By combining Australia’s discovery engine with Denmark’s translational ecosystem, we’re building a focused path to first-in-human trials by aligning manufacturing readiness, regulatory strategy, and clinical partnerships."
Addressing the Global Challenge of Heart Failure
Heart failure is a severe condition that affects over 60 million people worldwide. It occurs when the heart struggles to pump enough blood to meet the body’s needs. For patients with end-stage heart failure, heart transplants are the only viable option, but the significant shortage of donor organs remains an ongoing challenge. Ibnova Therapeutics seeks to address this gap by creating accessible and innovative treatments.
Professor James Hudson, also a Co-Founder of Ibnova Therapeutics, emphasized the importance of the company’s scientific foundation. "The technology was developed on the backing of over a decade of research into creating multicellular bioengineered tissues. The mechanistic science underpinning this technology is pivotal to its substantial improvement in heart function."
The foundational intellectual property underpinning Ibnova Therapeutics has been supported by numerous organizations, including reNEW, the Australian Research Council, the Medical Research Future Fund, and the National Health and Medical Research Council. This extensive backing has enabled the research team to bring its groundbreaking ideas closer to clinical reality.
A Vision for the Future
The BioInnovation Institute (BII) Venture Lab will play a crucial role in providing early-stage funding and guidance as Ibnova Therapeutics scales up its operations. The Novo Nordisk Foundation Cellerator will also contribute expertise in manufacturing engineered heart tissue to meet therapeutic standards.
Professor Melissa Little, Chief Scientist at MCRI and CEO of reNEW, praised the project’s progress as a testament to collaborative innovation. "The mission of reNEW is to move the very best stem cell science through to the development of new therapies. The formation of Ibnova Therapeutics from the research in the Australian node is precisely what we aim to achieve."
As Ibnova Therapeutics sets its sights on first-in-human clinical trials, the company represents a bold step forward in the quest to address one of the world’s most pressing medical challenges - offering hope to millions impacted by heart disease.